📰 French Study News
French Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from French Study. Real-time updates on events, politics, business and more.
October 16, 2023
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be...
October 15, 2023
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ubamatamab (MUC16xCD3) in recurrent ovarian cancer also to be presented Additional presentations on outcomes of Libtayo-based therapy in advanced non-small cell lung cancer, including PD-L1 expression and histology specific subgroups TARRYTOWN, N.Y., Oct...
October 15, 2023
16.10.2023 - Event-free survival of investigational use of Libtayo (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ...
January 16, 2023
Summary of Key Facts A Danish review of 79,102 female and 16,568 male subjects, found HPV vaccines had significantly ...
July 10, 2021
Schutz vor Coronavirus - Dritte Impfung als Chance für einen Teil der Immungeschwächten Einige Menschen entwickeln trotz zweifacher Impfung keinen guten Immunschutz gegen Covid-19. Eine dritte Dosis könnte laut einer neuen Studie zumindest manchen von ihnen helfen. Autor: Daniel Theis Bei Facebook teilen (externer Link, Popup) Bei Twitter teilen (externer Link, Popup) Mit What...